Back to Search Start Over

The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma.

Authors :
Kajiyama H
Suzuki S
Yoshikawa N
Tamauchi S
Shibata K
Kikkawa F
Source :
Journal of gynecologic oncology [J Gynecol Oncol] 2020 Jul; Vol. 31 (4), pp. e47. Date of Electronic Publication: 2020 Jan 08.
Publication Year :
2020

Abstract

Objective: The impact of systematic retroperitoneal lymphadenectomy (SRL) remains controversial in patients with advanced ovarian clear-cell carcinoma (CCC) who are optimally debulked.<br />Methods: Between 1986 and 2017, a total of 3,227 women with epithelial ovarian carcinoma were analyzed in a multi-institutional study. Among them, 166 optimally debulked women with stage IIB-IV CCC were collected (residual tumor of <1 cm). All patients were divided into 2 groups: 1) Group I (n=112): underwent standard radical surgery with SRL, 2) Group II (n=54): underwent non-staging limited surgery. The pathological slides were assessed based on central pathological review. Oncologic outcomes were compared between the two groups using a propensity score (PS)-matching technique to adjust for various clinicopathologic factors.<br />Results: The median follow-up duration of all surviving women was 52.8 (1.6-184.2) months. Overall, 88 patients (53.0%) experienced recurrence and 68 patients (41.0%) died of the disease. In the original cohort, the 5-year overall survival (OS) rates of groups I and II were 57.9 and 64.9%, respectively (log-rank p=0.415). In the PS-adjusted cohort, the 5-year OS rates were 64.9 and 58.8% in women in groups I and II, respectively (p=0.453). Furthermore, in the PS-matched cohort after adjustment for multiple clinicopathologic factors, there was no significant difference in OS between the 2 groups (group I vs. group II; hazard ratio=1.170; 95% confidence interval=0.633-2.187; p=0.615).<br />Conclusions: This study suggests that the performance of SRL including radical surgery may not lead to a significant improvement in the oncologic outcome of advanced CCC patients with optimal cytoreduction.<br />Competing Interests: No potential conflict of interest relevant to this article was reported.<br /> (Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.)

Details

Language :
English
ISSN :
2005-0399
Volume :
31
Issue :
4
Database :
MEDLINE
Journal :
Journal of gynecologic oncology
Publication Type :
Academic Journal
Accession number :
32026661
Full Text :
https://doi.org/10.3802/jgo.2020.31.e47